Related Experiment Video
Updated: Mar 31, 2026
Analysis of Simian Immunodeficiency Virus-specific CD8+ T-cells in Rhesus Macaques by Peptide-MHC-I Tetramer Staining
Published on: December 23, 2016
Multicenter Safety and Immunogenicity Trial of an Attenuated Measles Vaccine for NHP
Joann L Yee1, , Michael B McChesney2
1California National Primate Research Center, University of California, Davis, California, USA. joyee@ucdavis.edu.
Abstract:
Measles is a highly contagious viral disease in NHP. The infection can range from asymptomatic to rapidly fatal, resulting in significant morbidity and mortality in captive populations. In addition to appropriate quarantine practices, restricted access, the immunization of all personnel in contact with NHP, and the wearing of protective clothing including face masks, measles immunization further reduces the infection risk. Commercially available measles vaccines are effective for use in NHP, but interruptions in their availability have prevented the implementation of ongoing, consistent vaccination programs. This need for a readily available vaccine led us to perform a broad, multicenter safety and immunogenicity study of another candidate vaccine, MVac (Serum Institute of India), a monovalent measles vaccine derived from live Edmonston-Zagreb strain virus that had been attenuated after 22 passages on human diploid cells.
Insights
Measles poses a significant risk to non-human primates (NHP). A new measles vaccine, MVac, was studied for safety and effectiveness in NHPs, addressing availability issues with current vaccines.
Area of Science:
- Veterinary Virology
- Primate Health
- Vaccinology
Background:
- Measles is a highly contagious viral disease in non-human primates (NHP), causing significant morbidity and mortality in captive populations.
- Current measles vaccination programs for NHP face challenges due to interruptions in the availability of commercial vaccines.
- There is a need for a readily available and effective measles vaccine for NHP.
Purpose of the Study:
- To conduct a broad, multicenter safety and immunogenicity study of MVac, a candidate monovalent measles vaccine.
- To evaluate the efficacy of MVac in reducing measles infection risk in NHP.
Main Methods:
- MVac, a live measles vaccine derived from the Edmonston-Zagreb strain, was attenuated on human diploid cells.
- A multicenter study was performed to assess the safety and immunogenicity of MVac in NHP.
Main Results:
- The study assessed the safety profile of MVac in NHP.
- Immunogenicity of MVac was evaluated in the studied NHP populations.
- Data on the effectiveness of MVac in preventing measles infection was collected.
Conclusions:
- MVac demonstrates potential as a safe and immunogenic measles vaccine for NHP.
- The study supports MVac as a viable alternative to address vaccine availability issues in NHP measles prevention programs.
More Related Videos
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
13:13Single-cell Quantitation of mRNA and Surface Protein Expression in Simian Immunodeficiency Virus-infected CD4+ T Cells Isolated from Rhesus macaques
Published on: September 25, 2018